AI Insights · Timothy · July 2023
Top 5 Medical Apps Performance on iOS in Europe, Q2 2023
Explore the performance of the top 5 medical apps on the iOS platform in Europe during Q2 2023, focusing on trends in downloads, revenue, and active users.
In the second quarter of 2023, the top 5 medical apps on the iOS platform in Europe showed varied performance trends in weekly downloads, revenue, and active users. Here's a detailed look at their metrics:
SnoreLab : Record Your Snoring experienced a steady increase in weekly revenue, peaking at approximately $14.7K in late April. Weekly downloads saw a significant spike mid-April, reaching 9.5K, but gradually declined to around 4.3K by the end of June. Active users hit a high of 18.5K in late April but saw a downward trend, ending the quarter at about 12.8K.
AMBOSS Wissen für Mediziner maintained a consistent revenue stream, with weekly earnings fluctuating between $10.6K and $13.4K. Downloads peaked at 1.5K in late April before dropping to around 750 in early June, showing a slight recovery to nearly 1K by the end of the quarter.
Huckleberry: Baby & Child showed a positive revenue trend, with earnings reaching up to $11.4K in mid-June. Downloads were relatively stable, with a notable increase to 4.4K in late June. Active users displayed consistent engagement, peaking at 64.6K towards the end of May and maintaining a similar level through June.
FibriCheck showed consistent weekly revenue, ranging from $6.6K to $8.4K. Downloads remained steady, with minor fluctuations around the 2K mark. Active users hovered around 3.4K, indicating stable user engagement throughout the quarter.
Prime Sleep Recorder had a stable revenue stream, with weekly earnings ranging from $4.9K to $6.6K. Downloads saw a peak of 11.6K in mid-May before stabilizing around 6.3K by the end of June. Active users remained relatively stable, averaging around 27K to 30K throughout the quarter.
These insights are based on data from Sensor Tower. For more detailed analytics and trends, visit Sensor Tower's platform.